Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Vacca

Showing results (341-350 of 347) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 347 results.
Oncogene|October 4, 2011
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targetsS Berardi, A Caivano, R Ria, et al.
Leukemia|October 25, 2017
JAM-A as a prognostic factor and new therapeutic target in multiple myelomaA G Solimando, A Brandl, K Mattenheimer, et al.
Leukemia|October 22, 2015
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patientsM A Frassanito, K De Veirman, V Desantis, et al.
Oncogene|April 4, 2017
Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinomaA Po, M Silvano, E Miele, et al.
Folia Biologica|September 16, 2003
Allogeneic gene-modified tumour cells in metastatic kidney cancer. Preliminary reportG Pizza, C De Vinci, G Lo Conte, et al.
Leukemia|February 10, 2016
Targeting vasculogenesis to prevent progression in multiple myelomaM Moschetta, Y Mishima, Y Kawano, et al.
Leukemia Research|February 1, 2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese"G Mele, A Melpignano, G Quarta, et al.
Pageof 35

Showing results (341-350 of 347) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 347 results.
Oncogene|October 4, 2011
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targetsS Berardi, A Caivano, R Ria, et al.
Leukemia|October 25, 2017
JAM-A as a prognostic factor and new therapeutic target in multiple myelomaA G Solimando, A Brandl, K Mattenheimer, et al.
Leukemia|October 22, 2015
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patientsM A Frassanito, K De Veirman, V Desantis, et al.
Oncogene|April 4, 2017
Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinomaA Po, M Silvano, E Miele, et al.
Folia Biologica|September 16, 2003
Allogeneic gene-modified tumour cells in metastatic kidney cancer. Preliminary reportG Pizza, C De Vinci, G Lo Conte, et al.
Leukemia|February 10, 2016
Targeting vasculogenesis to prevent progression in multiple myelomaM Moschetta, Y Mishima, Y Kawano, et al.
Leukemia Research|February 1, 2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese"G Mele, A Melpignano, G Quarta, et al.
Pageof 35